COMPASS Pathways Reports Before Its FDA Timeline Becomes More Than a Projection

COMPASS Pathways (CMPS) reports Q2 2026 earnings on July 30, 2026, with analysts expecting a loss of $0.46 per share. The mental health biotech, focused on its investigational COMP360 psilocybin treatment for treatment-resistant depression, faces a critical test as investors assess progress in its Phase III program and cash runway. With the stock trading at $10.90 and analysts maintaining overwhelmingly bullish ratings despite recent volatility, this report will determine whether the company can sustain momentum following last quarter's strong beat.

Part 1: Earnings Preview

COMPASS Pathways is a mental health biotech company developing COMP360, a pharmaceutical-grade psilocybin formulation for treatment-resistant depression (TRD). The company is advancing a Phase III program in TRD while conducting Phase II trials in PTSD and anorexia nervosa, positioning itself at the forefront of psychedelic-assisted therapy development.

For Q2 2026, analysts expect CMPS to report a loss of $0.46 per share on July 30, 2026. The company most recently reported Q1 2026 results with an actual loss of $0.30 per share, beating estimates by 33.33%. Compared to the same quarter last year (Q2 2025), when CMPS reported a loss of $0.38 per share, the current consensus implies a 21.05% deterioration year-over-year.

Three key themes define this earnings story:

Phase III Trial Progress and Regulatory Pathway: Investors will scrutinize updates on COMPASS's Phase III program evaluating COMP360 in treatment-resistant depression. Any data readouts, enrollment milestones, or regulatory interactions with the FDA could significantly impact the stock, as the success of this program represents the company's primary value driver.

Cash Runway and Burn Rate: With no revenue generation and consistent quarterly losses, COMPASS's cash position and operating expenses remain critical. The company's ability to fund operations through key clinical milestones without dilutive financing will be closely watched, particularly given the $1.94 cash per share reported in recent filings.

Competitive Positioning in Psychedelic Medicine: As the psychedelic therapy space attracts increasing attention from both biotechs and major pharma, COMPASS's ability to maintain its lead in psilocybin development for depression will be scrutinized. Any partnerships, competitive developments, or differentiation in its therapy model could influence investor sentiment.

Analyst commentary ahead of the release reflects cautious optimism, with 15 of 18 analysts rating the stock a Strong Buy despite the expected loss widening year-over-year. The consensus appears focused on long-term potential rather than near-term profitability, with price targets ranging from $13.00 to $70.00.

Part 2: Historical Earnings Performance

COMPASS Pathways has demonstrated inconsistent earnings performance over the past four quarters, alternating between beats and misses with significant magnitude swings. In Q1 2026 (March), the company delivered its strongest performance with a loss of $0.30 versus the $0.45 estimate, representing a 33.33% beat. However, this followed a dramatic Q4 2025 (December) miss, where the company reported a loss of $0.59 against a $0.41 estimate, missing by 43.90%.

The pattern shows volatility in both directions: Q3 2025 (September) produced a modest 5.00% beat with a $0.38 loss versus $0.40 expected, while Q2 2025 (June) saw a small 2.70% miss at $0.38 versus $0.37 estimated. This inconsistency suggests difficulty in forecasting operating expenses and cash burn, likely reflecting the variable nature of clinical trial costs and timing.

The trend reveals no clear directional pattern—CMPS has alternated between beats and misses with no sustained momentum in either direction. The magnitude of surprises has been substantial, particularly the 43.90% Q4 miss and 33.33% Q1 beat, indicating that consensus estimates may struggle to capture the lumpiness of biotech R&D spending. Investors should expect continued volatility in earnings surprises as the company navigates its Phase III program.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

COMPASS Pathways typically reports earnings before market open, meaning Day 0 captures the first reaction session while Day +1 reflects follow-through trading.

COMPASS Pathways exhibits significant post-earnings volatility, with an average absolute Day 0 move of 10.06% and Day +1 follow-through averaging 3.97%. The most recent earnings on May 13, 2026, produced the largest reaction in the dataset—a 16.97% surge on Day 0 following the strong beat, though this was partially reversed with a 3.10% decline the following session. The stock has shown a tendency toward positive Day 0 reactions in five of the last eight reports, but the magnitude varies dramatically: from a 23.10% plunge in October 2024 to the recent 16.97% spike.

The Day 0 trading range averages 13.43%, indicating substantial intraday volatility regardless of direction, while Day +1 ranges average 9.26%, suggesting continued uncertainty as investors digest the results. Notably, the most recent quarter showed the highest Day 0 move but relatively modest Day +1 activity, suggesting the market quickly priced in the positive surprise. Investors should prepare for double-digit percentage swings on earnings day, with the direction heavily dependent on whether results beat or miss expectations.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 17.16% ($1.87) for the August 21 expiration, which is significantly higher than the historical average Day 0 move of 10.06%. This elevated implied volatility of 101.49% suggests options traders are anticipating a larger-than-typical reaction, possibly reflecting heightened uncertainty around clinical trial updates or cash burn guidance.

Part 3: What Analysts Are Saying

Analysts maintain overwhelmingly bullish sentiment on COMPASS Pathways, with 15 of 18 analysts rating the stock a Strong Buy, 1 Moderate Buy, and 2 Hold ratings. The average recommendation of 4.72 out of 5.00 reflects near-consensus optimism about the company's long-term prospects. The mean price target of $23.20 implies 113% upside from the current price of $10.90, with the high estimate of $70.00 suggesting some analysts see potential for more than 540% appreciation if clinical programs succeed.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 14 to 15. This upgrade activity suggests growing analyst confidence, possibly driven by the strong Q1 beat or positive developments in the Phase III program. The wide target range—from a low of $13.00 to a high of $70.00—reflects the binary nature of biotech investing, where clinical success could drive exponential returns while setbacks could limit upside.

The consensus view appears focused on COMPASS's position as a leader in psychedelic medicine rather than near-term financial performance, with analysts willing to look through continued losses toward potential regulatory approval and commercialization. The lack of any Sell ratings underscores the Street's conviction in the company's pipeline, though the two Hold ratings suggest some caution about valuation or execution risk at current levels.

Part 4: Technical Picture

COMPASS Pathways enters earnings with a deteriorating technical picture, as the Barchart Technical Opinion has weakened from 100% Buy one month ago to 64% Buy one week ago, and now stands at just 56% Buy. This steady decline in technical strength suggests momentum has faded significantly heading into the report, with the stock trading at $10.90 after pulling back from recent highs.

Timeframe Analysis:

• Short-term (50% Buy): Neutral-to-positive signal indicates near-term momentum has stalled, with bulls and bears in balance
• Medium-term (50% Buy): Moderate buy signal suggests the intermediate trend remains constructive but lacks conviction
• Long-term (100% Buy): Strong buy signal reflects positive momentum in the longer-term trend, indicating the broader uptrend remains intact

Trend Characteristics: The trend is characterized by Average strength with the Weakest direction, suggesting the stock is in a consolidation phase with diminishing momentum as it approaches earnings.

The stock is trading below its 5-day ($11.20), 10-day ($11.66), 20-day ($12.52), and 50-day ($12.41) moving averages, indicating short-term weakness and a potential downtrend in the immediate term. However, CMPS remains above its 100-day ($9.88) and 200-day ($8.18) moving averages, confirming the longer-term uptrend is still intact despite recent softness.

Key resistance now sits at the 20-day moving average of $12.52, which the stock would need to reclaim to reverse the recent downtrend. Support appears at the 100-day moving average of $9.88, just below current levels. The technical setup is cautionary heading into earnings—while the long-term trend remains positive, the stock has lost short-term momentum and is trading below all near-term moving averages. The 17.16% expected move suggests the market is pricing in significant volatility, and a strong beat would be needed to reclaim the 20-day moving average and restore bullish momentum. Conversely, a miss could test the 100-day support and potentially trigger a deeper correction.